| DHR |
Report |
Adj. EPS (operating) |
BEAT |
pred ~$1.93 vs. cons $1.838 |
HIGH |
| DHR |
Report |
Total Revenue |
IN-LINE |
pred ~$6.05B vs. cons $6.100B |
MEDIUM |
| DHR |
Report |
Biotech Segment Organic Growth |
BEAT |
pred ~+6.5% vs. cons ~+5.5% |
MEDIUM |
| DHR |
Guide |
FY 2026 Adj. EPS (FY 2026) |
BETTER |
guide ~$8.55-$8.65 vs. cons midpoint $8.45 |
MEDIUM |
| DHR |
Guide |
FY 2026 Core Revenue (FY 2026) |
UNCHANGED |
guide 3-6% maintained vs. current guide 3-6% |
HIGH |
| DHR |
Guide |
Bioprocessing Equipment Tone (Qualitative, FY 2026) |
BETTER |
guide upgrade from flat to modestly positive vs. current flat assumption |
LOW |
| DHR |
Return |
Day-1 residual (stock − beta × S&P 500) |
+3.5% |
— |
MEDIUM |
| DHR |
Return |
5-day cumulative residual |
+5.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — out-period math pulls H2 estimates up; short-cover bid; bioprocessing equipment narrative takes days to be reflected in models |
MEDIUM |